Back to Home
Free CE/CMEVideo

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Release Date

July 11, 2025

Expiration Date

July 12, 2026

Credits

2.0 CME, NCPD

Specialties

Gastrointestinal Cancer, General Oncology+3 more

Release Date: July 11, 2025

Expiration Date: July 11, 2026

Activity Overview

This educational activity is an archive of the live presentation held on May 30, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward physicians, nurses, NPs/PAs, and other HCPs involved in the treatment and management of colorectal cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Define key biomarkers that guide personalized treatment decision-making in patients with metastatic colorectal cancer (mCRC), incorporating multidisciplinary team support
  • Apply the latest data on current and emerging treatment options for mCRC, including targeted therapies (e.g., BRAF, HER2, KRAS), into clinical practice for optimal patient outcomes
  • Identify strategies for monitoring and managing adverse effects of current and emerging therapies for mCRC to ensure treatment adherence and patient safety
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.

Related Content

Course

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Create Account